The amount of the deal was not disclosed.
Led by Mr. Kevin McMahon, President and Chief Executive Officer, Solx develops innovative surgical technologies that treat glaucoma and preserve vision. Its lead product is the SOLX Gold Shunt™, an implantable drainage device designed to reduce elevated intraocular pressure (IOP) associated with refractory glaucoma without creating a bleb.
The device provides a pathway for the flow of aqueous humor from the anterior chamber to the suprachoroidal space, utilizing a natural pressure differential within the eye.
Approved for use in Canada and Europe, the SOLX Gold Shunt has been tested in a multi-center clinical trial, is investigational and awaiting FDA approval in the U.S.
The company is also backed by MVM Life Science Partners, River Street Management, Easton Capital, institutional and other investors.